Look back at pharma news to Apr 7
As we soon head into the first-quarter financial results reporting period, German family-owned pharma major Boehringer Ingelheim came to the fore, reporting its achievements for 2016. Also in the news were positive late-stage clinical results for Paratek Pharmaceuticals’ omadacycline, Astellas Pharma’s buy of Belgian firm Ogeda, lack of investor excitement despite a US approval for Teva Pharmaceutical Industries Huntington’s drug and questions over Tesaro’s PARP inhibitor.
Is this the turnaround Paratek has been looking for?
Shares of Paratek Pharmaceuticals saw a huge gain early on Tuesday after the company provided a critical update on its late-stage pneumonia trial, noted Chris Lang on 24/7WALLSt. Specifically, the firm reported positive top-line results from a global, pivotal Phase III clinical study comparing its once-daily oral and intravenous, broad spectrum investigational antibiotic, omadacycline, to moxifloxacin in the treatment of patients with community-acquired bacterial pneumonia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze